NIH Budget Tracks Doubling Goal

No one expects the events of Sept. 11-and the subsequent drains on the U.S. Treasury's surplus-to keep Congress from keeping its promise made in 1998 to double the National Institutes of Health budget by 2003. The proposed $22 billion-plus appropriation for Fiscal Year 2002 is close to the ensuing year's expected amount of about $26 billion. Congressional committee changes to President George W. Bush's NIH request prior to Sept. 11 have remained untouched. But the monies that Congress wants to

Written byChristine Bahls
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

But the monies that Congress wants to spend on bioterrorism research and other security measures will come from the treasury's surplus, recently projected to drop from $237 billion to $127 billion. "Clearly," says Melissa Merson, communications director for the Congressional Budget Office, "a substantial amount of the surplus is being consumed. It's not unlikely that we will end up with a deficit for 2002."

So the question-and some say it's rhetorical-that could be asked is: what will happen after the NIH budget is doubled? Will the increases continue to keep pace with the commitments that the NIH has made to its grant recipients, in the face of a near-certain recession and surplus-less treasury? According to Bill Burton, spokesman for Sen. Tom Harkin, (D-Iowa) chairman of the Labor, Health and Human Services, and Education appropriations subcommittee, right now, Harkin is focused on the 2002 allotment. "Where the 2003 numbers come from, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies